Excreted Unchanged %
70-80
Half-Life (Normalesrd) Hours
5-11/20
Plasma Protein Binding %
36
Volume Of Distribution L/Kg
0.8-1.3
Dose For Normal Renal Function
150-300 mg q12-24h
Adjustment For Renal Failure Method
D, I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50-150 mg q24h (full first dose) [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
25-50 mg q24h (50 mg first dose) [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data: Dose for GFR <10
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 100 mg first day, then 50 mg/day, [D]
References
Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996; 40: 1514-9. [PMID: 8726029] / Izzedine H, Launay-Vacher V, Deray G. Dosage of lamivudine in a haemodialysis patient [Letter]. Nephron. 2000; 86: 553. [PMID: 11124630] / Johnson MA, Verpooten GA, Daniel MJ, Plumb R, Moss J, Van Caesbroeck D, et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol. 1998; 46: 21-7. [PMID: 9690945] / Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol. 1995; 35: 1174-80. [PMID: 8750368]
Toxicity Notes
Extraction ratio with HD ~53-65%.